Clinical trial · Interventional
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
NCT00186238CI-TRIAL-00003902completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To assess the role of autologous hematopoietic cell rescue in the treatment of multiple myeloma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| high dose chemotherapy then autologous hematopoietic cell transplant | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Toxicity and efficacy of sequentially administered high dose chemotherapy and autologous hematopoietic cell transplantation
- timeFrame
- Patients will have a daily CBC with platelet count, and chemistries until engraftment, then as indicated clinically. Chest x-rays will be done weekly until engraftment, then as indicated clinically. Patients will be restaged for abnormal proteins (SPIE)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria:- received cytoreduction prior to transplant * adequate organ function Exclusion Criteria:- previous transplant * smoldering MM or benign monoclonal gammopathy
References
Publications (0)
Data not yet available
No reference posted for this study.